The long-term goal of this project is to define the normal and pathological roles of the synucleins, and in particular alpha-synuclein. Alpha-synuclein has emerged as a major focus of investigation because of an apparent (but poorly understood) role both in neurodegenerative disease and in normal synaptic plasticity and learning.
The first aim for the next project period is to complete a formal biophysical characterization of human alpha-synuclein (halphaS), focusing on its ability to interact with membrane lipids and to self-associate.
This aim will be conducted in collaboration with Dr. Seelig of the University of Basel.
A second aim i s to compare the properties of mutant synucleins linked to the development of Parkinson's disease, as well as a non-human (canary) alpha-synuclein, to gain insight into which features are specifically conserved and which may be more likely related to pathology.
A third aim i s to use site-directed mutagenesis to construct mutant forms of recombinant halphaS with altered lipid binding properties. This will provide insight into the functional organization of the sequence, and will generate mutant constructs potentially useful for probing synuclein's cellular functions.
A fourth aim i s to map the sites upon which synuclein is phosphorylated by the protein Casein Kinase II, and to investigate the structural and functional consequences of this modification on lipid binding and phospholipase D2 inhibition. A fifth aim will employ the various recombinant constructs produced and characterized in Aims 1-4, to probe the mechanisms by which synuclein can exert effects on cell function. In collaboration with Dr. Hyman of the Massachusetts General Hospital, the hypothesis that lipid binding is necessary for cell membrane association will be formally tested, and the necessity of lipid binding for both presynaptic terminal localization and PLD2 inhibition will also be tested. Collectively, these experiments test the hypothesis that synuclein's essential molecular function is related to its conserved structural features, which allow it to bind reversibly with intracellular membranes. Manipulation of these interactions could have uses in the development of therapies for age-related diseases including Alzheimer's and Parkinson's diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG013762-05
Application #
6372068
Study Section
Special Emphasis Panel (ZRG1-MDCN-2 (01))
Program Officer
Finkelstein, Judith A
Project Start
1997-01-15
Project End
2005-07-31
Budget Start
2001-08-01
Budget End
2002-07-31
Support Year
5
Fiscal Year
2001
Total Cost
$299,597
Indirect Cost
Name
University of Illinois Urbana-Champaign
Department
Biochemistry
Type
Schools of Arts and Sciences
DUNS #
041544081
City
Champaign
State
IL
Country
United States
Zip Code
61820
Hasadsri, Linda; Kreuter, Jörg; Hattori, Hiroaki et al. (2009) Functional protein delivery into neurons using polymeric nanoparticles. J Biol Chem 284:6972-81
Woods, Wendy S; Boettcher, John M; Zhou, Donghua H et al. (2007) Conformation-specific binding of alpha-synuclein to novel protein partners detected by phage display and NMR spectroscopy. J Biol Chem 282:34555-67
Payton, Jacqueline E; Perrin, Richard J; Woods, Wendy S et al. (2004) Structural determinants of PLD2 inhibition by alpha-synuclein. J Mol Biol 337:1001-9
Perrin, R J; Payton, J E; Barnett, D H et al. (2003) Epitope mapping and specificity of the anti-alpha-synuclein monoclonal antibody Syn-1 in mouse brain and cultured cell lines. Neurosci Lett 349:133-5
George, Julia M (2002) The synucleins. Genome Biol 3:REVIEWS3002
Perrin, R J; Woods, W S; Clayton, D F et al. (2001) Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J Biol Chem 276:41958-62
Perrin, R J; Woods, W S; Clayton, D F et al. (2000) Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. J Biol Chem 275:34393-8
Clayton, D F; George, J M (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. J Neurosci Res 58:120-9
Clayton, D F; George, J M (1998) The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci 21:249-54
Davidson, W S; Jonas, A; Clayton, D F et al. (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 273:9443-9

Showing the most recent 10 out of 11 publications